Securities code: 002589 securities abbreviation: Realcan Pharmaceutical Group Co.Ltd(002589) Announcement No.: 2022-003 Realcan Pharmaceutical Group Co.Ltd(002589)
Stock trading abnormal fluctuation announcement
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Introduction to abnormal fluctuations in stock trading
The stock trading price of Realcan Pharmaceutical Group Co.Ltd(002589) (stock abbreviation: Realcan Pharmaceutical Group Co.Ltd(002589) , stock code: 002589, hereinafter referred to as the “company”) has deviated from the closing price by more than 20% in three consecutive trading days on January 11, 2022, January 12, 2022 and January 13, 2022. According to the relevant provisions of the stock listing rules of Shenzhen Stock Exchange, It belongs to abnormal fluctuation of stock trading.
2、 Description of the company’s concern and verification
In view of the abnormal fluctuation of the company’s stock trading, the company conducted a self-examination and verified the relevant matters with the controlling shareholders, actual controllers, shareholders holding more than 5%, all directors, supervisors and senior managers of the company. The relevant information is explained as follows:
1. There is no need to correct or supplement the information disclosed by the company in the early stage;
2. The company has not found any unpublished material information that may or has had a great impact on the stock trading price of the company reported by the public media recently;
3. Recently, the company’s production and operation are normal, and the internal and external business environment has not changed significantly;
4. After asking the controlling shareholders, actual controllers, shareholders holding more than 5% of the shares, all directors, supervisors and senior managers of the company, there are no major events that should be disclosed but not disclosed about the company, nor are there major events in the planning stage;
5. Upon inquiry, the controlling shareholders, actual controllers and shareholders holding more than 5% of the company’s shares, and all directors, supervisors and senior managers did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
3、 Whether there is a description of information that should be disclosed but not disclosed
The board of directors of the company confirms that the company has no undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matters that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions; The board of directors has not been informed that the company has undisclosed information that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions and has a great impact on the stock trading price of the company; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Necessary risk tips
1. The company has not violated the fair disclosure of information through self-examination;
2. The company solemnly reminds investors: securities times, China Securities News, Shanghai Securities News, securities daily and cninfo（ http://www.cn.info.com.cn. ）As the information disclosure media designated by the company, all information of the company shall be subject to the information published in the above designated media. The company will conscientiously perform the obligation of information disclosure and do a good job of information disclosure in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations.
Please invest rationally and pay attention to risks.
It is hereby announced.
Realcan Pharmaceutical Group Co.Ltd(002589) board of directors
January 14, 2022
